Wedbush maintains Ultragenyx Pharma neutral, cuts $23 target
Wedbush maintains a neutral rating on Ultragenyx Pharma and cuts its price target to $23.00 from $30.00, according to Benzinga ratings action summarized by TradingView News.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.